Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
1999-01-14
2001-09-04
Saoud, Christine (Department: 1647)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S071100, C435S471000, C435S320100, C435S252300, C435S325000, C536S023100, C536S023500, C536S024500, C530S351000
Reexamination Certificate
active
06284487
ABSTRACT:
BACKGROUND OF THE INVENTION
Long chain fatty acids (LCFAs) are an important source of energy for most organisms. They also function as blood hormones, regulating key metabolic functions such as hepatic glucose production. Although LCFAs can diffuse through the hydrophobic core of the plasma membrane into cells, this nonspecific transport cannot account for the high affinity and specific transport of LCFAs exhibited by cells such as cardiac muscle, hepatocytes, enterocytes, and adipocytes. The molecular mechanisms of LCFA transport remains largely unknown. Identifying these mechanisms can lead to pharmaceuticals that modulate fatty acid uptake by various organs, thereby alleviating certain medical conditions (e.g. obesity).
SUMMARY OF THE INVENTION
Described herein are members of a diverse family of fatty acid transport proteins (FATPs) which are evolutionarily conserved; these FATPs are plasma membrane proteins which mediate transport of LCFAs across the membranes and into cells. Members of the FATP family described herein are present in a wide variety of organisms, from mycobacteria to humans, and exhibit very different expression patterns in tissues. FATP family members are expressed in prokaryotic and eukaryotic organisms and comprise characteristic amino acid domains or sequences which are highly conserved across family members.
As described herein, four novel mouse FATPs, referred to as mmFATP2, mmFATP3, mmFATP4 and mmFATP5, and five human FATPs, referred to as, hsFATP2, hsFATP3, hsFATP4, hsFATP5 and hsFATP6, have been identified. Human FATPs 2-5 have orthologs in mice; the sixth human FATP (hsFATP6) does not as yet have a mouse ortholog. The expression patterns of these FATPs vary, as described below.
The present invention relates to FATP family members from prokaryotes and eukaryotes, nucleic acids (DNA, RNA) encoding FATPs, and nucleic acids which are useful as probes or primers (e.g., for use in hybridization methods, amplification methods) for example, in methods of detecting FATP-encoding genes, producing FATPs, and purifying or isolating FATP-encoding DNA or RNA. Also the subject of this invention are antibodies (polyclonal or monoclonal) which bind an FATP or FATPs; methods of identifying additional FATP family members (for example, orthologs of those FATPs described herein by amino acid sequence) and variant alleles of known FATP genes; methods of identifying compounds which bind to an FATP or to a polypeptide comprising a portion of a FATP, or modulate or alter (enhance or inhibit) FATP function; compounds which modulate or alter FATP function; methods of modulating or altering (enhancing or inhibiting) FATP function and, thus, LCFA uptake into tissues of a mammal (e.g., human) by administering a compound or molecule (a drug or agent) which increases or reduces FATP activity; and methods of targeting compounds to tissues by administering a complex of the compound to be targeted to tissues and a component which is bound by an FATP present on cells of the tissues to which the compound is to be targeted. For example, a complex of a drug to be delivered to the liver and a component which is bound by an FATP present on liver cells (e.g., FATP5) can be administered. In a further embodiment, LCFA uptake by the liver is modulated or altered (enhanced or reduced), in an individual. For example, a drug which inhibits the function of an FATP present in liver (e.g., FATP5) is administered to an individual who is diabetic, in order to reduce LCFA uptake by liver cells and, thus reduce insulin resistance.
The present invention, thus, provides methods which are useful to alter, particularly reduce, LCFA uptake in individuals and, as a result, to alter (particularly reduce), availability of the LCFAs for further metabolism. In a specific embodiment, the present invention provides methods useful to reduce LCFA uptake and, thus, fatty acid metabolism in individuals, with the result that caloric availability from fats is reduced, and circulating fatty acid levels are lower than they otherwise would be. These methods are useful, for example, as a means of weight control in individuals, (e.g., humans) and as a means of preventing elevated serum lipid levels or reducing serum lipid levels in humans.
The identification of this evolutionarily conserved fatty acid transporter family will allow a better understanding of the mechanisms whereby LCFAs traverse the lipid bilayer as well as yield insight into the control of energy homeostasis and its dysregulation in diseases such as diabetes and obesity.
REFERENCES:
patent: 4935450 (1990-06-01), Cone, Jr.
Uchiyama, A. et al., “Molecular Cloning of cDNA Encoding Rat Very Long-chain Acyl-CoA Synthetase,”J. Biol. Chem. 271(48):30360-30365 (1996).
Stuhlsatz-Krouper, S.M. et al., “Substitution of Alanine for Serine 250 in the Murine Fatty Acid Transport Protein Inhibits Long Chain Fatty Acid Transport,”J. Biol. Chem. 273(44):28642-28650 (1998).
Watkins, P.A. et al., “Disruption of theSaccharomyces cerevisiae FAT1Gene Decreases Very Long-chain Fatty Acyl-CoA Synthetase Activity and Elevates Intracellular Very Long-chain Fatty Acid Concentrations,”J. Biol. Chem. 273(29):18210-18219 (1998).
Hirsch, D. et al., “A family of fatty acid transporters conserved from mycobacterium to man,”Proc. Natl. Acad. Sci. 95:8625-8629 (1998).
Berger, J. et al., “A Novel Relative of the Very-Long-Chain Acyl-CoA Synthetase and Fatty Acid Transporter Protein Genes with a Distinct Expression Pattern,”Biochem. Biophys. Res. Commun. 247:255-260 (1998).
Hui, T.Y. et al., “Characterization of the Murine Fatty Acid Transport Protein Gene and Its Insulin Response Sequence,”J. Biol. Chem. 273(42):27420-27429 (1998).
Færgeman, N.J. et al., “Disruption of theSaccharomyces cerevisiaeHomologue to the Murine Fatty Acid Transport Protein Impairs Uptake and Growth on Long-chain Fatty Acids,”J. Biol. Chem. 272(13):8531-8538 (1997).
Schaap, F.G. et al., “Molecular cloning of fatty acid-transport protein cDNA from rat,”Biochem. Biophys. Acta 1354:29-34 (1997).
Schaffer, J.E. and Lodish, H.F., “Expression Cloning and Characterization of a Novel Adipocyte Long Chain Fatty Acid Transport Protein,”Cell(79):427-436 (1994).
Bonaldo, M.F. et al.; Data Submission;Rattus norvegicuscDNA clone;Rattus norvegicus; GenBank Accession No. AA817672;(1996).
Schaap, F.G. et al.; Data Submissioin;Rattus norvegicusfatty acid transport protein mRNA, complete cds.;Rattus norvegicus; GenBank Accession No. U89529; (1997).
Lee, N.H. et al.; Data Submission; Normalized rat heart, Bento SoaresRattus sp. cDNA clone;Rattus sp.; GenBank Accession No. AA799326; (1998).
Hui, T.Y. et al.; Data Submission;Mus musculusfatty acid transport protein (FATP) gene, exons 1-3;Mus musculus; GenBank Accession No. AF023256; (1997).
Schaffer, J.E. and Lodish, H.F.; Data Submission;Mus musculusfatty acid transport protein (FATP) mRNA, complete cds.;Mus musculus; GenBank Accession No. U15976 (1994).
Stahl, A. et al.; Data Submission;Mus musculusfatty acid transport protein 5 mRNA, complete cds.;Mus musculus; GenBank Accession No. AF072760; (1998).
Stahl, A. et al.; Data Submission;Mus musculusfatty acid transport protein 4 mRNA, partial cds.;Mus musculus; GenBank Accession No. AF072759; (1998).
Stahl, A. et al.; Data Submission;Mus musculusfatty acid transport protein 3 mRNA, partial cds.;Mus musculus; GenBank Accession No. AF072758; (1998).
Stahl, A. et al.; Data Submission;Mus musculusfatty acid transport protein 2 mRNA, complete cds.;Mus musculus; GenBank Accession No. AF072757; (1998).
Hui, T.Y. et al.; Data Submission;Mus musculusfatty acid transport protein (FATP) gene, exons 4-7;Mus musculus; GenBank Accession No. AF023257; (1997).
Hui, T.Y. et al.; Data Submission;Mus musculusfatty acid transport protein (FATP) gene, exons 8-13 and complete cds.;Mus musculus; GenBank Accession No. AF023258; (1997).
Kamijo, K.; Data Submission;Homo sapiensmRNA for very-long-chain acyl-CoA synthetase, complete cds.;Homo sapiens(human); EMBL Accession No. D88308; (1996).
Harmon, C.M. et al., “Labelling of an 88 kDa adipocyte membrane protein by
Hirsch David J.
Lodish Harvey F.
Stahl Andreas
Hamilton Brook Smith & Reynolds P.C.
Hamud Fozia
Saoud Christine
Whitehead Institute for Biomedical Research
LandOfFree
Polynucleotides encoding fatty acid transport proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polynucleotides encoding fatty acid transport proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polynucleotides encoding fatty acid transport proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2489263